The genetic basis of cancer is increasingly understood, driving significant advances in personalized medicine.  Next-generation sequencing technologies have revolutionized our ability to comprehensively profile tumor genomes, identifying driver mutations and other genomic alterations that contribute to tumorigenesis. This detailed genomic information allows for the stratification of patients into distinct subgroups based on their molecular profiles, moving beyond traditional histological classifications.  Consequently, targeted therapies, designed to specifically inhibit the products of oncogenic mutations or exploit specific tumor vulnerabilities, are becoming increasingly prevalent.  Recent developments include the identification of novel therapeutic targets through the discovery of fusion genes and the characterization of the tumor microenvironment's genomic landscape. Immunotherapy, leveraging the power of the patient's immune system, has also been significantly refined by understanding the genomic context of immune evasion mechanisms within tumors.  Furthermore, the integration of genomic data with other -omics data, such as transcriptomics and proteomics, provides a more holistic understanding of tumor biology, leading to the development of more effective and less toxic treatment strategies.  This personalized approach, while facing challenges related to cost and accessibility, promises to significantly improve cancer patient outcomes through precision diagnosis and tailored treatments.